Dietary Supplement Startup Compliance

The Scenario

Consider a direct-to-consumer dietary supplement startup founded by entrepreneurs with backgrounds in fitness and nutrition, aiming to create premium sports nutrition supplements sold primarily through e-commerce channels. The walkthrough below shows how Assurentry's workflows apply — the company and figures are illustrative.

The Challenge

Like many supplement startups, the founders in this scenario are experts in their product domain but have limited knowledge of FDA regulations. Their contract manufacturer handles production, but compliance responsibilities are murky — and a peer company recently received an FDA warning letter that nearly destroyed its business, prompting the founders to seek expert help.

When we reviewed their planned product launch, we identified multiple issues that would have triggered FDA enforcement action. The company was 6 weeks from launch with packaging already in production.

The Solution

We developed a comprehensive pre-launch compliance program that addressed immediate issues while building sustainable compliance infrastructure:

Phase 1: Emergency Label Correction (Week 1-2)

• Complete review of all 8 product labels against DSHEA (Dietary Supplement Health and Education Act) requirements and 21 CFR Part 101.36 (Supplement Facts panel requirements)
• Rewrote claims to compliant structure/function format under Section 403(r)(6) of the FD&C Act -- replaced prohibited disease claims ("prevents muscle soreness") with permitted structure/function claims ("supports muscle recovery")
• Corrected Supplement Facts panel formatting: proper nutrient listing order, Daily Value percentages, serving size declarations, and "Other Ingredients" listing per 21 CFR 101.36
• Added the mandatory DSHEA disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
• Coordinated with packaging vendor to implement changes within the existing print timeline, saving $15,000 in reprint costs

Phase 2: Facility and Manufacturing Compliance (Week 2-4)

• Audited contract manufacturer for cGMP compliance under 21 CFR Part 111 -- the specific GMP regulation for dietary supplements (distinct from the drug GMP regulation, 21 CFR Part 211)
• Identified 12 gaps in Part 111 compliance including inadequate identity testing of incoming ingredients, incomplete batch production records, and missing stability data
• Established a formal quality agreement between the brand and the contract manufacturer, defining responsibilities for raw material testing, in-process testing, finished product testing, and complaint handling
• Created product specifications and testing requirements including identity, purity, strength, composition, and contamination limits per 21 CFR 111.75

Phase 3: Compliance Infrastructure (Week 3-6)

• Completed FDA food facility registration (dietary supplements are classified as food under FDA) and obtained the facility FEI number
• Submitted structure/function claim notifications to FDA within 30 days of marketing, as required by Section 403(r)(6) -- filed notifications for all 8 products listing each specific claim
• Created adverse event reporting procedures compliant with the Dietary Supplement and Nonprescription Drug Consumer Protection Act -- established the 15-business-day serious AE reporting timeline to FDA
• Evaluated whether any ingredients required New Dietary Ingredient (NDI) notification under Section 413(a)(2) of the FD&C Act (21 USC 350b) -- determined all ingredients had sufficient history of use pre-1994
• Developed compliant marketing review process to catch prohibited claims before publication
• Trained customer service team on complaint handling, adverse event identification, and the internal escalation process

The Results